SCHEMBL1144191

SCHEMBL1144191

CC(C)(C)OC(=O)N1CCN(C(=O)c2c(Cl)n(-c3ccccc3)c3ccccc23)CC1

nearest known ligand 0.52

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.52
CHRM4 P08173 1/20 0.52
CHRM1 P11229 1/20 0.52
CHRM3 P20309 1/20 0.52
POLB P06746 1/20 0.47
GPR119 Q8TDV5 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
REN P00797 10/20 0.47
CNR2 P34972 1/20 0.46
TP53 P04637 1/20 0.43
THRB P10828 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1144687 0.89 REN (0.53) CHRM2CHRM4CHRM1CHRM3POLB
SCHEMBL1150502 0.88 REN (0.50) CHRM2CHRM4CHRM1CHRM3POLB
SCHEMBL1149614 0.88 REN (0.50) POLBGPR119MEN1KMT2AREN
SCHEMBL1144661 0.88 ALDH1A1 (0.44) CHRM2CHRM4CHRM1CHRM3POLB
SCHEMBL1144186 0.88 REN (0.48) CHRM2CHRM4CHRM1CHRM3POLB
SCHEMBL1144092 0.87 ALDH1A1 (0.61) CHRM2CHRM4CHRM1CHRM3POLB
SCHEMBL1144600 0.87 ALDH1A1 (0.51) POLBGPR119MEN1KMT2AREN
SCHEMBL1150314 0.84 POLB (0.56) POLBGPR119MEN1KMT2AREN
SCHEMBL1149725 0.84 POLB (0.56) POLBREN
SCHEMBL1144901 0.84 REN (0.69) REN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2247575-B1 CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2016-03-23 EP disclosed
US-8211885-B2 Cyclic indole-3-carboxamides, their preparation and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2012-07-03 US disclosed
US-20110039830-A1 CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2011-02-17 US disclosed
EP-2247575-A2 CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2010-11-10 EP disclosed
WO-2009095163-A2 CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2009-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039830-A1 CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS REN, ACE, PM20D2 CHRM2 173/4885CHRM4 426/4885CHRM1 147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.